

СРПСКИ АРХИВ

ЗА ЦЕЛОКУПНО ЛЕКАРСТВО

SERBIAN ARCHIVES

OF MEDICINE

Paper Accepted*

ISSN Online 2406-0895

Original Article / Оригинални рад

Nataša Đorđević¹, Sanja Matić², Dragan Milovanović^{1,3}, Srđan Stefanović², Suzana Popović^{4,*}, Danijela Todorović⁵, Predrag Đurđević^{6,7}, Predrag Sazdanović^{8,9}, Vasilije Antić¹⁰, Slavica Lončar¹⁰, Slavica Bukumira¹¹, Marko Radenković¹¹, Tijana Šusteršić^{12,13}, Nenad Filipović^{12,13}, Dejan Baskić^{4,14}

Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-CoV-2 – a Serbian cohort study

Ефективност треће дозе вакцине ковида 19 против делта варијанте вируса SARS-CoV-2

- кохортна студија заснована на подацима из Србије

¹University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacology and Toxicology, Kragujevac, Serbia;

²University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, Kragujevac, Serbia;

³Kragujevac University Clinical Centre, Department of Clinical Pharmacology, Kragujevac, Serbia;

⁴University of Kragujevac, Faculty of Medical Sciences, Centre for Molecular Medicine and Stem Cell Research, Kragujevac, Serbia;

⁵University of Kragujevac, Faculty of Medical Sciences, Department of Genetics, Kragujevac, Serbia;

⁶University of Kragujevac, Faculty of Medical Sciences, Department of Internal medicine, Kragujevac, Serbia;

⁷Kragujevac University Clinical Centre, Clinic for Hematology, Kragujevac, Serbia;

⁸University of Kragujevac, Faculty of Medical Sciences, Department of Anatomy, Kragujevac, Serbia;

⁹Kragujevac University Clinical Centre, Clinic for Gynecology and Obstetrics, Kragujevac, Serbia;

¹⁰Kragujevac Primary Health Centre, Kragujevac, Serbia;

¹¹Kragujevac Primary Health Centre, Department of Social Medicine, Kragujevac, Serbia;

¹²University of Kragujevac, Faculty of Engineering, Kragujevac, Serbia;

¹³Bioengineering Research and Development Center (BioIRC), Kragujevac, Serbia;

¹⁴Kragujevac Institute of Public Health, Serbia;

Received: December 17, 2022 Revised: July 16, 2023 Accepted: September 6, 2023 Online First: September 8, 2023 DOI: https://doi.org/10.2298/SARH221217082D

*Accepted papers are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the *Serbian Archives of Medicine*. They have not yet been copy-edited and/or formatted in the publication house style, and the text may be changed before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. Srp Arh Celok Lek. Online First, February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

*Correspondence to: Suzana POPOVIĆ Svetozara Markovica 69, 34000 Kragujevac, Serbia E-mail: suzana.popovic@medf.kg.ac.rs

Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-CoV-2 – a Serbian cohort study

Ефективност треће дозе вакцине ковида 19 против делта варијанте вируса SARS-CoV-2 – кохортна студија заснована на подацима из Србије

SUMMARY

Introduction/Objective The duration of vaccineinduced protection against SARS-CoV-2 is shown to be limited. The aim of this study was to assess vaccine effectiveness (VE) of a third dose of four different COVID-19 vaccines during Delta variant predominance in Serbia.

Methods The data for the period from Aug 18th to Oct 1st 2021, were used to estimate the incidence rates of the SARS-CoV-2 infection, COVID-19-related hospitalization, and intensive care unit (ICU) admission. The study included 41,186 fully vaccinated subjects, of which 13,589 had received the third dose. VE was estimated based on the incidence rate ratio following vaccination with three versus two doses.

Results We found that a third dose of all investigated vaccines reduces the incidence of both SARS-CoV-2 infection and severe illness that requires hospitalization or ICU admission. The highest VE against infection demonstrated BNT162b2, followed by Gam-COVID-Vac and BBIBP-CorV. Third dose vaccination reduced the risk of hospitalization (incidence rate IR = 0 for Gam-COVID-Vac and BBIBP-CorV), and ICU admission (IR = 0 for all vaccines). The hazard distributions for SARS-CoV-2 infection and hospitalization following vaccination with three versus two doses were significantly different.

Conclusion These findings indicate that an additional, third dose of studied vaccine boosters protection against all investigated outcomes.

Keywords: COVID-19; vaccine effectiveness; BBIBP-CorV; Gam-COVID-Vae; BNT162b2; ChA-dOx1nCoV-19

Сажетак

Увод/Циљ Показало се да је заштита коју пружа вакцина против SARS-CoV-2 временски ограничена. Зато је циљ ове студије био да се процени ефективност (ЕВ) четири различите вакцине против ковида 19 после примања треће дозе. Истраживање је спроведено у Србији током доминације Делта варијанте SARS-CoV-2.

Методе Подаци за период од 18. августа до 1. октобра 2021. коришћени су за процену стопе инциденције инфекције SARS-CoV-2, хоспитализације због ковида 19 и пријема у јединицу интензивне неге (ЈИН). Студија је обухватила 41.186 субјеката вакцинисаних са најмање две дозе, од којих је 13.589 примило и трећу дозу. ЕВ је процењена на основу односа стопе инциденције након вакцинације са три у односу на две дозе.

Резултати Трећа доза свих испитиваних вакцина смањила је учесталост и SARS-CoV-2 инфекције и тешког облика болести који захтева хоспитализацију или пријем у интензивну негу. Највећу ЕВ против инфекције показала је вакцина BNT162b2, а затим Gam-COVID-Vac и BBIBP-CorV. Трећа доза вакцине смањила је ризик од хоспитализације (стопа инциденције ИР = 0 за Gam-COVID-Vac и BBIBP-CorV) и пријема у интензивну негу (ИР = 0 за све вакцине). Расподела ризика за инфекцију SARS-CoV-2 и хоспитализацију након вакцинације са три у односу на две дозе су се значајно разликовале.

Закључак Добијени резултати указују на то да додатна, трећа доза испитиваних вакцина појачава заштиту од свих испитиваних исхода.

Кључне речи: ковид 19; ефективност вакцине; *BBIBP-CorV*; *Gam-COVID-Vac*; *BNT*162b2; *ChAdOx*1*nCoV*-19

INTRODUCTION

In March 2020, the World Health Organization declared the pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). During the last two years, the multiple waves of COVID-19 pushed healthcare systems to the breaking point; lockdowns and mobility restrictions left severe consequences on the economy; and social distancing and isolation heavily disrupted human physical and mental wellbeing. The world has been witnessing the magnitude, the extent and the continuance of the perturbations COVID-19 brought on to all spheres of human life, yet - only less than 10% of

humanity has been infected with the SARS-CoV-2 so far (https://covid19.who.int/), and the virus continues to spread globally.

The virus spreading can be stopped only by achieving herd immunity - either by infection or by vaccination. SARS-CoV-2 infection, unlike vaccination, enables virus transmission to nonimmune people, and in those who are infected could take severe form, lead to hospitalization or intensive care unit admission, and end fatally. Hence, the safest and the most effective way to achieve protection against COVID-19 is vaccination. Up to now, about 11.3 billion doses of a COVID-19 vaccine have been administered globally, and 64.6% of the world population has received at least one dose [1]. Although vaccination reduces the possibility of infection and lessens the risk of developing severe form of the disease, it has been reported that the SARS-CoV-2 specific response, even after receiving the second dose of vaccine, diminishes over time [2, 3].

Since the waning immunity, especially in the presence of new viral strains, warrants booster immunization, data on a third dose vaccine effectiveness (VE) are of great importance. The main aim of this study was to assess VE of a third dose of four different COVID-19 vaccines, namely BNT162b2 (Comirnaty®, Pfizer-BioNTech), BBIBP-CorV (Vero Cell®, Sinopharm), Gam-COVID-Vac (Sputnik V®, Gamaleya Institute) and ChAdOx1-nCoV-19 (Vaxzevria®, University of Oxford/AstraZeneca), during Delta variant predominance in Serbia.

METHODS

Study design

This retrospective comparative cohort study was conducted among the resident population of the city of Kragujevac, Serbia, between August 18th, 2021 (start of a third dose of COVID-19 vaccines rollout in Serbia) and October 1st, 2012. To be included in the study, subjects needed to be older than 16 years of age and completely vaccinated against SARS-CoV-2 (i.e. to have received at least two doses of either BBIBP-CorV, Gam-COVID-Vac, BNT162b2, or ChAdOx1-nCoV-19 vaccine) by the end of the study follow up. However, as the neutralizing antibody levels, which are highly predictive of vaccine efficacy against SARS-CoV-2 infection [4], decrease substantially until 3 months after vaccination [5], recipients of only two doses were included only if the second dose was received at least 3 months before the beginning of the study. Subjects were excluded from the analyses if the data on sex, age,

vaccination status, and COVID-19 test results were not available, but also if infection with SARS-CoV-2 took place prior to vaccination, or within the first seven days after receiving the vaccine (Figure 1).

The data on vaccination coverage was extracted from the Serbian National Immunization Registry. The Reports of the Primary Health Centre and the University Clinical Centre in Kragujevac provided information on the study outcomes, namely RT-PCR or antigen test confirmed SARS-CoV-2 infection, hospitalization due to COVID-19 and COVID-19-related intensive care unit (ICU) admission. Subjects were followed up either from the beginning of the study (if they had been vaccinated earlier), or from the day of receiving the last dose of the vaccine; until the end of the study, or until they had been diagnosed with COVID-19. According to available data [6], the Delta variant was the most predominant (if not the sole) circulating strain of SARS-CoV-2 in Serbia during the study period.

The study was approved by the Ethics committee at the University Clinical Centre and the Primary Health Centre, Kragujevac, Serbia (approvals No 01/20-405, No 01/20-497 and No 01-1148/1, obtained on April 3rd, 2020, May 5th, 2020 and February 24th, 2021, respectively), and conducted in accordance with the Declaration of Helsinki and its subsequent revisions.

Statistical analysis

SPSS Statistics, version 20 (IBM, Armonk, NY, USA) and Stata Statistical Software, release 16 (StataCorp LLC, Texas, USA) were used for statistical analyses. The frequencies of the COVID-19-related events were expressed as incidence rates (IR). Vaccine effectiveness (VE) against all study outcomes was determined based on the sex- and age-adjusted incidence rate ratio (IRR) among those vaccinated with either two or three COVID-19 vaccine doses. Vaccine-preventable disease incidence (VPDI), the parameter that more directly presents an impact of the vaccines on reducing infection, hospitalization, and ICU admission, is a measure of the difference in the incidence of any particular outcome between vaccinated and unvaccinated populations, and was calculated according to Gessner et al. [7]. The number needed to vaccinate (NNV), i.e., the number of people or vaccine doses needed to prevent the investigated outcomes, was calculated according to Tripepi et al. [8]. To compare hazard distributions for the study outcomes following vaccination with three versus only two doses,

the Kaplan-Meier method and a log rank (Mantel-Cox) test were used. P values of less than 0.05 were considered significant.

RESULTS

Demographic characteristics, type of vaccine received, and the total length of follow up of all subjects involved in the study, stratified according to the vaccination status, are presented in Table 1. As subjects participating in the study were followed for different lengths of time, a cumulative amount of time (Total person time) was calculated as the sum of the total time contributed by all subjects.

The third dose of any vaccine, as compared to only two doses, decreased the overall IRs of SARS-CoV-2 infection, hospitalization due to COVID-19 and COVID-19-related ICU admission. The frequencies of COVID-19-related study outcomes in both cohorts (overall and per vaccine type), and the measures of VE against SARS-CoV-2 infection and hospitalization in subjects vaccinated with three doses, are presented in Table 2.

The complete absence of ICU admission among subjects vaccinated with three doses of any vaccine, as well as hospitalization among those who have received three doses of Gam-COVID-Vac or BNT162b2, precluded VE estimation against these outcomes. The VE of ChAdOx1-nCoV-19 could not be assessed due to the lack of subjects receiving this type of vaccine in three doses. Similarly, only one recipient of only two doses received two different vaccine types, preventing assessment of heterologous prime-boost strategy effectiveness.

Cumulative hazard functions comparing the incidence of the study outcomes following vaccination with three versus only two doses of any of the four available COVID-19 vaccines are presented in Fig 2. The hazard distributions for SARS-CoV-2 infection and hospitalization due to COVID-19 were significantly different ($\chi^2(1) = 150.468$, p < 0.0001 and $\chi^2(1) = 21.404$, p < 0.0001, respectively). The comparison could not be made for ICU admission, due to the lack of this event among subjects vaccinated with the third dose.

DISCUSSION

Our main finding is that a third dose of any of the four investigated COVID-19 vaccines, as compared to the second dose received at least 3 months ago, significantly reduces the incidence of Delta variant SARS-CoV-2 infection, but also the incidence of hospitalization due

to COVID-19, and COVID-19-related ICU admission. Our results support the recommendation of administration of a booster dose in general adult population to restore protection against COVID-19 and its complications.

In terms of infection, the highest VE of a third versus two doses in our study reached almost 93% in those vaccinated with BNT162b2, with as little as 3 subjects that needed to be vaccinated with a booster dose of BNT162b2 or Gam-COVID-Vac to prevent 1 case of COVID-19. To prevent 1 hospitalization, a third dose of any of the COVID-19 vaccines investigated in our study had to be given to 21 subjects fully vaccinated at least 3 months ago, and VE of the booster reached almost 85%. On the other hand, rare admissions to ICU after receiving two doses, and none in a third dose group, precluded assessment of third dose VE and NNT. In line with our findings, a retrospective cohort study from Israel, comparing infection rates among nearly a million subjects vaccinated with either two or three doses of BNT162b2 vaccine, reported third dose VE of 89.1% [9]. Another Israeli study on almost 1 and a half million participants estimated VE of three versus two BNT162b2 doses to be 93% for hospital admission [10]. Similarly, a large study from United States, conducted on almost half a million veterans, reported 84% and 77% VE of three as compared to two doses of BNT162b2 vaccine against symptomatic SARS-CoV-2 Delta strain infection and COVID-19related hospitalization, respectively [11]. Among more than a million subjects from California, who were vaccinated with either two or three doses of BNT162b2, VE of a third dose reached 75% against infection and 70% against hospital admission [12]. Again, study from United States, conducted during Delta predominance across 10 states and more than 250 hospitals, estimated BNT162b2 vaccine third-dose effectiveness against hospitalization and ICU admission due to COVID-19, when compared to unvaccinated population, to reach 94% [13]. In the limited number of studies concerning the effectiveness of three versus two doses of SARS-CoV-2 vaccines, the BNT162b2 vaccine, as the first one approved by WHO, was clearly by far the most investigated [9, 10, 13-15]. Yet, there are several other vaccines against COVID-19 deployed worldwide [16], calling for the future research to widen the scope, and include not only other internationally available vaccines, but also both available concepts of vaccination - homologous and heterologous [17].

As for the BBIBP-CorV vaccine, while the large-scale effectiveness studies are lacking, strong SARS-CoV-2 specific immunity after the third dose has been reported [18-20]. Similarly, it has been observed that a third dose of ChAdOx1-nCov-19 boosts T-cell response and increases antibody titers [21]. On the other hand, there were no available reports on Gam-

COVID-Vac vaccine boosting. In our study, considerable effectiveness of a booster dose of the same vaccine type against of SARS-COV-2 infection was confirmed for three out of four investigated vaccines. Namely, due to the specific dosing regimen and the relatively short follow-up, our study did not include subjects who had received three doses of ChAdOx1-nCov-19. We were also unable to calculate third dose VE of a mix-and-match prime-boost strategy, as the only subject in the two-dose group who was vaccinated with different vaccine types did not get infected with SARS-CoV-2. Nevertheless, it is worth noting that among over 3,000 subjects, whose third dose of the vaccine differed from the previous two (mix and match approach), only about 0.5% got COVID-19 during the follow-up, and none was hospitalized or admitted to ICU. Our results correspond well to the previous reports showing that the immunogenicity of a heterologous third dose boost was as good as, or better than homologous [22-25], especially in fighting against newer SARS-CoV-2 variants of concern [26]. However, after the third vaccine dose, the same level of protection was achieved in both the homologous and heterologous COVID-19 vaccination regimens [27, 28].

The Omicron variant, first identified in South Africa in November 2021 as highly transmissible, has become a globally dominant strain. The Omicron has raised significant global concern due to its large number of mutations, which may impact the effectiveness of vaccines and therapeutics. According to emerging real-world data, the VE of COVID-19 vaccines against symptomatic infection due to Omicron is lower than for the Delta variant, although all vaccines provide high levels of protection against hospitalization and death [29]. However, several studies have shown that the decline in two-dose vaccine VE against Omicron could be increased or restored by a third vaccine dose [30], emphasizing the importance of booster vaccination.

The limitations of the present study include the short follow-up time after the third dose, single-strain- and a single-center study design, but also the lack of data on many potential confounders, such as the level of exposure to SARS-CoV-2; potential behavioral changes after vaccination; possible under-reporting of COVID-19-like symptoms; asymptomatic (thus undiagnosed) COVID-19 cases; coexisting illnesses and immunocompromising conditions; as well as other medical and demographic risk factors that might affect the susceptibility to COVID-19, and the severity and the outcome of the disease.

Despite the limitations of the present study, our results speak in favor of booster vaccination as a necessity in controlling the COVID-19 pandemic. In a view of a waning immunity against SARS-CoV-2 and the emergence of new virus variants, periodic vaccine boosting will most probably become indispensable in future years.

ACKNOWLEDGMENT

This report is independent research supported by Primary Health Centre Kragujevac (PHCK), Kragujevac, Serbia and University Clinical Centre Kragujevac (UCCK), Kragujevac, Serbia. We thank Dejan Stevanovic from PHCK and Vladan Todorovic from UCCK for technical support. We also thank PHCK COVID-19 Vaccine Coverage team, all staff supporting study delivery at participating sites and all participants for their ongoing commitment and contributions to this study.

Funding: The study was financially supported by the Science Fund of the Republic of Serbia, the program IDEAS, grant No. 7749739.

Conflict of interest: None declared.

REFERENCES

- 1. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav 2021;5(7):947-53. 10.1038/s41562-021-01122-8.
- Israel A, Merzon E, Schäffer AA, Shenhar Y, Green I, Golan-Cohen A, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ. 2021;375. 10.1136/bmj-2021-067873. PMC9083235.
- Thompson RN, Hill EM, Gog JR. SARS-CoV-2 incidence and vaccine escape. Lancet Infect Dis 2021;21(7):913-4. 10.1016/S1473-3099(21)00202-4. PMC8043582.
- 4. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-11. 10.1038/s41591-021-01377-8.
- Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. New Eng J Med 2021;385(24):e84. 10.1056/NEJMoa2114583. PMC8522797.
- Knezevic A VD, Jankovic M, Milicevic O, Tesovic B, Jovanovic T. The Role of Whole-genome Sequencing in COVID-19 Pandemic. The First World Conference Fighting COVID-19 Pandemic -Health Challenges; 26-28 March 2022; Belgrade: MEDAPP Association 2022. p. 60.
- Gessner BD, Feikin DR. Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. Vaccine. 2014;32(26):3133-8. 10.1016/j.vaccine.2014.04.019. PMC4772886.
- 8. Tripepi G, Jager KJ, Dekker FW, Zoccali C. Measures of effect in epidemiological research. Nephron Clin Pract. 2010;115(2):c91-c3. 10.1159/000312870.
- 9. Saciuk Y, Kertes J, Shamir Stein N, Ekka Zohar A. Effectiveness of a third dose of BNT162b2 mRNA vaccine. J Infect Dis 2022;225(1):30-3. 10.1093/infdis/jiab556. PMC8689889.
- Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093-100. 10.1016/S0140-6736(21)02249-2. PMC8555967.
- Butt AA, Talisa VB, Yan P, Shaikh OS, Omer SB, Mayr FB. Vaccine Effectiveness of Three vs. Two Doses of SARS-CoV-2 mRNA Vaccines in a High Risk National Population. Clin Infect Dis. 2022. 10.1093/cid/ciac178. PMC8903438.
- 12. Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. Lancet Reg Health Am. 2022:100198. 10.1016/j.lana.2022.100198. PMC8841530.
- 13. Thompson MG, Natarajan K, Irving SA, Rowley EA, Griggs EP, Gaglani M, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance—VISION Network, 10 States, August 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):139-45. 10.15585/mmwr.mm7104e3. PMC9351525.
- 14. Perez JL. Efficacy & safety of BNT162b2 booster -C4591031 2 month interim analysis. In: Pfizer L, editor.; November 19, 2021; Atlanta, GA2021.
- Spitzer A, Angel Y, Marudi O, Zeltser D, Saiag E, Goldshmidt H, et al. Association of a third dose of BNT162b2 vaccine with incidence of SARS-CoV-2 infection among health care workers in Israel. JAMA 2022. 10.1001/jama.2021.23641. PMC8749710.
- Kim D, Pekgün P, Yildirim İ, Keskinocak P. Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach. Vaccine. 2021;39(47):6876-82. 10.1016/j.vaccine.2021.10.025. PMC8520874.
- 17. Sapkota B, Saud B, Shrestha R, Al-Fahad D, Sah R, Shrestha S, et al. Heterologous prime–boost strategies for COVID-19 vaccines. J Travel Med 2021. 10.1093/jtm/taab191. PMC8754745.
- Ai J, Zhang Y, Zhang H, Zhang Q, Fu Z, Lin K, et al. Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study: Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting. Emerg Microbes Infect. 2022(just-accepted):1-36. 10.1038/s41562-021-01122-8. 33972767.

- 19. Ju B, Zhou B, Song S, Fan Q, Ge X, Wang H, et al. Potent antibody immunity to SARS-CoV-2 variants elicited by a third dose of inactivated vaccine. Clin Transl Med. 2022;12(2). 10.1002/ctm2.732. PMC8882237.
- Zhang Y, Yang Y, Qiao N, Wang X, Ding L, Zhu X, et al. Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults. Front Medicine 2022;16(1):93-101. 10.1007/s11684-021-0914-x. PMC8815383.
- 21. Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). The Lancet. 2021;398(10304):981-90. 10.1016/S0140-6736(21)01699-8. PMC8409975.
- Al Kaabi N, Yang YK, Du LF, Xu K, Shao S, Liang Y, et al. Safety and immunogenicity of a hybridtype vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial. medRxiv. 2022. 10.1038/s41467-022-31379-0. PMC9237056.
- Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022. 10.1056/NEJMoa2116414. PMC8820244.
- 24. Munro AP, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258-76. 10.1016/S0140-6736(21)02717-3. PMC8639161.
- 25. Prasithsirikul W, Pongpirul K, Nopsopon T, Phutrakool P, Pongpirul W, Samuthpongtorn C, et al. Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers. Vaccines. 2022;10(2):217. 10.3390/vaccines10020217. PMC8878194.
- 26. Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MB, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399(10324). 10.1016/S0140-6736(22)00094-0. PMC8782575.
- 27. Guibert N, Trepat K, Pozzetto B, Josset L, Fassier J-B, Allatif O, et al. A third vaccine dose equalizes the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens. Eurosurveillance. 2023:2023.02. 13.23285853. 10.1101/2023.02.13.23285853.
- Lyke KE, Atmar RL, Dominguez Islas C, Posavad CM, Deming ME, Branche AR, et al. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. NPJ Vaccines. 2023;8(1):98. 10.1038/s41541-023-00693-z. PMC10336079.
- 29. Agency UHS. COVID-19 vaccine surveillance report: week 23 [updated 8 June 2023. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1164 943/vaccine-surveillance-report-2023-week-23.pdf.
- Lavender B, Hooker C, Frampton C, Williams M, Carson S, Paterson A, et al. Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naive New Zealand cohort. medRxiv. 2023:2023.03. 30.23287981. 10.1101/2023.03.30.23287981.

Parameters	Vaccinated with 3 doses		Vaccinated w	Total				
	n	%	n	%	n	%		
Total	13,589	33	27,597	67	41,186	100		
Age groups (years)								
Up to 24	36	0.26	464	1.68	500	1.21		
25–34	180	1.32	1769	6.41	1949	4.73		
35–44	807	5.94	4527	16.4	5334	12.95		
45–54	1327	9.77	4692	17	6019	14.61		
55-64	2502	18.41	5807	21.04	8309	20.17		
65–74	5888	43.33	6882	24.94	12,770	31.01		
75 and over	2849	20.97	3456	12.52	6305	15.31		
Sex								
Male	6538	48.11	12,639	45.8	19,177	46.56		
Female	7051	51.89	14,958	54.2	22,009	53.44		
Type of vaccine								
BBIBP-CorV	8477	62.38	17,270	62.58	25,747	62.51		
Gam-COVID-Vac	1139	8.38	5022	18.2	6161	14.96		
BNT162b2	944	6.95	4536	16.44	5480	13.31		
ChAdOx1-nCoV-19	0	0	768	2.78	768	1.86		
Mix-and-match	3,029	22.29	1	0	3030	7.36		
Total person time								
In days	315,033		1,179,279		1,494,312			
In years	863.1		3,230	4094				

of subjects involved in the study

^aSecond vaccine dose received at least three months before the beginning of the study followup

Table 2. The effectiveness of the third dose of COVID-19 vaccine^a as compared to two vaccine

doses^b in terms of SARS-CoV-2 infection, hospitalization due to COVID-19, and COVID-19-

related ICU admission

Infection, hospitalization, ICU admission	Number of events (IR) 3 doses ^a / 2 doses ^b	IRR (95% CI)	VE (95% CI), %	NNV	VPDI (95% CI)				
SARS-CoV-2 infection									
Any type of vaccine	164 (190) / 1,684 (521.2)	0.394 (0.334;0.464)	60.6 (53.6; 66.6)	3	289.9 (248.7; 329)				
BBIBP-CorV	139 (256) / 1,164 (577.7)	0.494 (0.413; 0.591)	50.6 (40.9; 58.7)	4	265.7 (210.1; 321.4)				
Gam-COVID-Vac	7 (154.5) / 299 (507.4)	0.335 (0.159; 0.707)	66.5 (29.3; 84.1)	3	310.2 (182.7; 437.7)				
BNT162b2	1 (22.7) / 180 (335.7)	0.074 (0.011; 0.510)	92.6 (49.0; 98.9)	3	295.2 (227.9; 362.7)				
ChAdOx1-nCoV-19	0 (ND) / 41 (454.3)	ND							
Mix and match	17 (73.6) / 0 (0)	ND							
Hospitalization due to COVID-19									
Any type of vaccine	8 (9.3) / 126 (39)	0.154 (0.073; 0.235)	84.6 (67.5; 92.7)	21	42.2 (34.8; 59.7)				
BBIBP-CorV	8 (14.7) / 113 (56.1)	0.190 (0.090; 0.398)	81.0 (60.2; 91.0)	21	47.6 (35.6; 59.5)				
Gam-COVID-Vac	0 (0) / 8 (13.6)	ND		74	13.6 (4.2; 23)				
BNT162b2	0 (0) / 5 (9.3)	ND		108	9.3 (1.2; 17.5)				
ChAdOx1-nCoV-19	0 (ND) / 0 (0)	ND							
Mix and match	0 (0) / 0 (0)	ND							
COVID-19-related ICU admission									
Any type of vaccine	0 (0) / 7 (2.2)	ND		455	2.2 (0.6; 3.8)				
BBIBP-CorV	0 (0) / 6 (3)	ND)	333	3.0 (0.6; 5.4)				
Gam-COVID-Vac	0 (0) / 0 (0)		NE)					
BNT162b2	0 (0) / 1 (1.9)	ND)	526	1.9 (1.8; 5.5)				
ChAdOx1-nCoV-19	0 (ND) / 0 (0)	ND							
Mix and match	0 (0) / 0 (0)	ND							

IR – crude incidence rate (per 1,000 person-years); IRR – incidence rate ratio adjusted for age and sex; VE – vaccine effectiveness; NNV – number needed to vaccinate; VPDI – vaccine-preventable disease incidence (per 1000 person-years);

^a3rd vaccine dose received at any time during the study follow-up;

^b2nd vaccine dose received at least 3 months before the beginning of the study follow-up;

^c heterologous prime-boost strategy applied;

NA - not applicable; ND - not determined (due to zero vaccinated or zero event count)



Figure 1. The cohorts' selection process;

*since the launch of the COVID-19 vaccines roll out in Serbia, until October 31, 2021



Figure 2. Cumulative hazard function comparing the incidence of a) SARS-CoV-2 infection, b) hospitalization due to COVID-19, and c) COVID-19-related ICU admission, following vaccination with three (green) versus only two (blue) doses of any of the four available COVID-19 vaccines; the dashed vertical line indicates day 7, when the analyses began